To overcome the immunosuppressive microenvironment of prostate cancer, PSMA targeting CAR-T cells that co-express dominant negative transforming growth factor β (TGF-β) type II receptor have been developed, and enhanced tumor eradication were seen in prostate cancer mouse models [111,112]. This evidence concerns the gene FOLH1 and prostate carcinoma.